HJ445A
HJ445A is a potent MYOF inhibitor and binds to the MYOF-C2D domain with a KD of 0.17 μM. HJ445A potently repressed the proliferation of gastric cancer cells with IC50 values of 0.16 and 0.14 μM in MGC803 and MKN45, respectively. HJ445A demonstrates superior antitumor efficacy in vivo and can be used for cancer research[1].
Product Specifications
CAS Number
3032441-59-8
UNSPSC
12352005
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hj445a.html
Concentration
10mM
Purity
98.31
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CCC1=NN(C2=CC=CC(C(NCCCCN3N=CC=N3)=O)=C2)C(C4=CC=C(C=C4)OC)=N1
Molecular Formula
C24H27N7O2
Molecular Weight
445.52
References & Citations
[1]Haijun Gu, et al. Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer. J Med Chem. 2023 Dec 6.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-B190040-2.5MG 2.5 mg
1,2,4-Benzenetricarboxylic Acid 1,4-Bis(2-ethylhexyl) Ester
Sign In for Pricing
View Details 
BNC940819-500 1x 500 µL
Caldesmon, HMW (h-Caldesmon) (h-CALD), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
